11/26/2007 | SS | Bradley Pharmaceuticals' founder to back Nycomed deal
|
10/30/2007 | SS | Bradley Pharmaceuticals valued at $346 million in deal with Nycomed
|
10/30/2007 | SS | Market Commentary: Merrill's departure of CEO sends shares down; Bradley Pharma shares zoom on Nycomed merger
|
6/4/2007 | SS | Bradley Pharmaceuticals to consider alternatives, Glassman group proposal
|
6/4/2007 | SS | Market Commentary: Doral gets rival bid; Accredited deal pushes Novastar; Cadence climbs; Solectron drives Sanmina
|
5/29/2007 | BK | Bradley management-led buyout bid backed by debt commitment from Credit Suisse
|
5/29/2007 | SS | Bradley Pharmaceuticals CEO, investor group, propose taking the company private for $21.50 per share
|
5/8/2007 | SS | Bradley Pharmaceuticals' non-executive chairman resigns
|
11/10/2006 | BT | Bradley kept at sector perform by RBC
|
11/8/2006 | BT | Bradley Pharmaceuticals: net sales for third quarter fall 14%
|
11/2/2006 | BT | Bradley kept at sector perform by RBC
|
9/28/2006 | BKBT | Bradley Pharmaceuticals amends loan to allow for stock repurchases
|
8/28/2006 | BT | Bradley to in-license phase 2, 3 drugs, implement cost-reduction program
|
8/18/2006 | BT | Bradley, Polymer agree to development terms
|
8/16/2006 | BT | Bradley Pharmaceuticals: complaint filed against company regarding board expansion
|
7/27/2006 | BT | Bradley launches nine generic products
|
7/19/2006 | BT | Bradley gets sector perform rating from RBC
|
6/30/2006 | BT | Bradley: FDA extends approval date for Polyphenon E genital wart ointment
|
6/26/2006 | BT | Bradley Pharmaceuticals at sector perform by RBC
|
6/23/2006 | BT | Bradley first-quarter net sales climb 5% to $34.8 million
|
5/26/2006 | BT | Bradley at sector perform by RBC
|
5/25/2006 | BT | RBC puts Bradley at sector perform
|
5/19/2006 | BKBT | Bradley Pharmaceuticals gets waiver of financial filing delay
|
5/1/2006 | BKBT | Bradley Pharmaceuticals looking for waiver of financial filing delay default
|
3/3/2006 | BT | Bradley Pharmaceuticals says sales up 36% to $102.4 million for first nine months of 2005
|
1/31/2006 | BT | Bradley, MediGene sign deal to commercialize genital wart cream Polyphenon E in United States
|
1/9/2006 | BKBTDD | Bradley defaults on loan as statement delivery deadline is missed
|
1/4/2006 | BT | Bradley Pharmaceuticals creates A. Aarons subsidiary to market generic drugs
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
12/23/2005 | BT | Bradley launches new dermatology products to minimize effects of generic competition
|
12/14/2005 | BT | Bradley, Par form licensing, distribution agreement for Adoxa antibiotic
|
11/15/2005 | BKBTCVDD | Bradley gets $110 million credit facility, repays all 4% convertibles
|
10/14/2005 | BT | Market Commentary: Predix, Electro-Optical IPOs imminent; Durect gains on trial news; Voyager IPO talk seen aggressive
|
9/22/2005 | BKBTCVDD | Bradley Pharmaceuticals' replacement credit facility closing pushed back to Nov. 9
|
6/7/2005 | BKCVDD | Bradley Pharmaceuticals defaults on convertibles, loan; payment blockage period enforced
|
4/28/2005 | BKCVDD | Bradley Pharmaceuticals receives default notice from noteholders, loan forbearance expires
|
9/28/2004 | BK | Market Commentary: Graham cuts term loans' pricing; Culligan breaks; Calpine rallies on bond, convertible clearing
|
9/21/2004 | BK | Market Commentary: Jostens lowers pricing on term B; Amsted soft call addition to repricing seems to please investors
|
9/1/2004 | BK | Bradley Pharmaceuticals $100 million credit facility to launch Thursday
|
7/24/2003 | CV | Bradley convertibles increased to $37 million through greenshoe, add-on
|
6/6/2003 | CV | Bradley Pharmaceuticals $25 million convertibles yield 4%, up 15%
|